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ABSTRACT 
Objective: The study involved development of transdermal delivery system (TDDS) of doxazosinmesylate (doxa) to achieve effective systemic 
delivery of the drug. 
Methods: TDDS of doxa was prepared using hydroxypropyl methyl cellulose (HPMC) K100LV and polyvinyl pyrrolidone (PVP) K30 in 3:1 ratio 
solvent casting method. The formulation was evaluated for folding endurance, moisture uptake, pH, drug content and in vitro permeation. Various 
permeation enhancers were incorporated at 5% w/w concentration into the patch formulationto study their impact on the drug permeation. The 
TDDS made with Transcutol® as an enhancer was subjected to accelerated stability studies and in vivo skin irritation studies. 
Results: The developed TDDS showed folding endurance of 170, moisture uptakeof 15.7%, pH of 6.3, and drug content of 99±1.1% and 66% in vitro 
permeation of doxa over 24h. The effect of various enhancers expressed in terms of average flux can be summarized as Transcutol® (10.6±2.1 
µg/cm2h)>dimethyl sulfoxide(10.17±1.2 µg/cm2h)>benzyl alcohol (9.55±1.3 µg/cm2h)>no enhancer (8.86±1.1 µg/cm2h)>dimethyl isosorbide (8.21±1.5 
µg/cm2h)>Isostearic acid (7.82±1.4 µg/cm2h)>propylene carbonate (7.67±1.4 µg/cm2h)>oleic acid (7.12 µg±0.8/cm2
Keywords: Doxazosinmesylate, Transdermal patch, Permeation enhancers, Polyvinyl pyrrolidone, Hydroxypropyl methylcellulose, Transcutol® 
h). The formulation was found to 
be stable during the accelerated stability studies. In vivo studies indicated absence of skin irritation effect the TDDS containing Transcutol®. 
Conclusion: TDDS of doxa comprising HPMC K100LV and PVPK30 in the ratio of 3:1 and 5% Transcutol® could serve as a potential TDDS in the 
treatment of benign prostatic hyperplasia (BPH) and hypertension. 




The transdermal route of administration is recognized as one of the 
potential routes for the systemic delivery of drugs. It offers many 
advantages over conventional oral administration such as the 
absence of hepatic first-pass metabolism, enhanced efficacy, lesser 
side effects, increased safety, reduced frequency of administration, 
greater convenience, and improved patient compliance. It excludes 
the variables that affect drug absorption from the gastrointestinal 
tract such as pH, enzymatic activity and drug-food interactions. A 
number of marketed preparations and the studies reported in the 
literature indicate that this approach of drug delivery is more 
pertinent in the case of diseases or disorders which require long-
term dosing to maintain therapeutic drug concentration and also for 
the ones which present untoward side effects upon oral 
administration [1-4]. Doxazosin mesylate (doxa) is used in the 
treatment of benign prostatic hyperplasia (BPH) as well as 
hypertension [5-7]. Its marketed preparations include oral 
conventional and controlled release formulations [8]. Reported 
studies have attempted development of orally disintegrating tablets, 
fast dissolving tablets, sustained release pellets and pulsatile 
delivery for the drug [9-12]. However, oral therapy of doxa is 
associated with only 65% bioavailability owing to first pass effect 
[13] and also with side effects like postural hypotension, dizziness, 
fatigue, headache, edema, and vertigo [8]. Development of a 
transdermal drug delivery system (TDDS) for doxa could overcome 
the first pass effect improving overall bioavailability and also 
eliminate the adverse effects. Smaller dose of 4-8 mg, the molecular 
weight of lesser than 600 Daltons, slight solubility in water and 
favorable partition coefficient of 2.1 makes doxa a suitable candidate 
for development of TDDS. There is enough evidence in literature 
wherein various anti-hypertensive drugs have been tried for the 
development of TDDS like metoprolol tartarate [14], nifedipine [15], 
amlodipine [16] and alfuzosin hydrochloride to name a few [17]. 
However, there is only one study that reports development TDDS of 
doxa where in doxa in combination with finasteride is incorporated 
in a gel type reservoir system constituted by poloxamer 407 and 
hydroxypropyl cellulose [18]. No attempt so far has been made to 
develop matrix type film formulation of doxa which being a solid 
unit dosage form offers advantages of accuracy of dose, ease of 
handing and overall improved convenience. Therefore, the aim of 
the present study was to develop TDDS of doxa using matrix type 
transdermal patches by solvent casting technique employing 
suitable polymers. The further aim of the study was to evaluate the 
influence of various permeation enhancers on the permeation 
profile of the drug. 
MATERIALS AND METHODS 
Materials 
Doxa was obtained as a gift sample from Dr. Reddy’s Laboratories, 
Hyderabad, India. Hydroxypropyl methyl cellulose (HPMC) K4M and 
K100LV, ethyl cellulose 7 cps (EC) were obtained as gift samples 
from Colorcon Asia Pvt. Ltd, Mumbai, India. Polyvinyl pyrrolidone 
K30 (PVP K30), polyethylene glycol (PEG) 400 and glycerin were 
purchased from Analab Finechem Pvt. Ltd, Pune, India. Transcutol®, 
oleic acid, dimethyl sulfoxide, iso-stearic acid, benzyl alcohol, and 
dimethyl isosorbide were obtained as gift samples from Cadila 
Healthcare Ltd., Mumbai, India. All other chemicals used were of 
analytical grade. 
Methods 
Standard plot of doxa 
Accurately weighed 10 mg quantity of doxa was dissolved in 
methanol and volume was made up to 10 ml with methanol. From 
the above solution, 1 ml was withdrawn and diluted up to 100 ml 
with phosphate buffer saline pH 7.4 (PBS). From this solution, 
suitable quantities were taken and diluted with PBS to get 2 µg/ml, 4 
µg/ml, 6 µg/ml, 8 µg/ml, 10 µg/ml. Absorbance was recorded at 246 
nm against PBS as blank on a UV spectrophotometer (Shimadzu 
1700, Japan). The standard plot was obtained by plotting absorbance 
versus concentration. 
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Selection of polymer combinations for development of TDDS 
The placebo patches were prepared by solvent casting technique [19]. 
Various polymer combinations used are shown in table 1. Polymers 
were weighed accurately as per the described composition in the table 
and dissolved in a sufficient quantity of methanol. In each polymeric 
solution, glycerin (2% w/w), PEG 400 (4% w/w) and distilled water 
(10% w/w) were added with continuous stirring. The weight of each 
solution was made up of methanol. The solution was poured into a 
petri plate placed on the leveled surface to form a uniform layer and 
dried in an oven at 40° C to form a film. The film was then carefully 
removed and cut into patches of 2.5 cm ×2.5 cm dimensions. 
 
Table 1: Preparation of placebo patches using various polymer combinations 
No. Polymers used  Compositions 












































HPMC K 100LV-hydroxypropyl methyl cellulose K 100 LV, HPMC K4M–hydroxypropyl methyl cellulose K4M, PVP K30–polyvinyl pyrrolidone K30, 
EC-ethyl cellulose 7 cps 
 
Evaluation of placebo patches 
The patches prepared using various polymer combinations were 
evaluated for following parameters [20-24]. 
Physical appearance 
The patches were visually inspected for colour, clarity, consistency, 
and smoothness. 
Thickness 
Thickness of the patches (5 no.) was determined by using screw 
gauge and the average thickness was determined. 
Folding endurance 
Folding endurance was determined by repeatedly folding a patch at the 
centre until it broke. The number of times, the patch could be folded at 
the same place without breaking was recorded as folding endurance.  
Moisture uptake 
Pre-weighed patches (5 no.) were placed in the desiccator 
containing 100 ml of saturated potassium chloride solution and kept 
for 24 h. Next day, the weight of each patch was recorded. Moisture 
uptake was calculated using the following formula. 
Moisture uptake =  




Pre-weighed patches (5 no.) were placed in the desiccator 
containing anhydrous calcium chloride. The final weight was noted 
after 24 h. The moisture loss for each patch was calculated using the 
formula.  
Moisture loss =
Initial weight − Final weight
Initial weight
× 100 
Development of TDDS of doxa 
Based on the evaluation of placebo patches, five polymer 
combinations viz. A1, A5, B1, D2 and D3
Accurately weighed amount of doxa as mentioned in table 2 was 
dissolved in a sufficient quantity of methanol. The solution of 
polymers was prepared separately in methanol using a magnetic 
stirrer. Weighed quantities of purified water, PEG 400 and glycerin 
(table 2) were added to polymer solution under stirring.  
from table 1 were chosen for 
development of TDDS of doxa. 
The drug solution was added at the end to the polymer solution, 
mixed well and the weight was made up with methanol. The solution 
was poured evenly in a petri plate, dried at 40° C in an oven over the 
period of 12-14 h. The patches (2.5 cm X 2.5 cm) of each formula 
were subjected to following evaluation parameters. 
 
Table 2: TDDS development of doxa 
Ingredient (% w/w) FA1 FA5 FB1 FD2 FD3 
Doxa 0.25 0.25 0.25 0.25 0.25 
HPMC K100LV  1.5 1 1.5 - - 
HPMC K4M  - - - 1 0.5 
PVP K 30 0.5 1 - - - 
EC  - - 0.5 0.5 0.5 
Glycerin 2 2 2 2 2 
 PEG 400  4 4 4 4 4 
Purified water 10 10 10 10 10 
Methanol  q. s 100  q. s 100  q. s 100  q. s 100  q. s 100  
 
Evaluation of TDDS 
The patch formulations of doxa were subjected to following 
evaluation parameters [20-24]. 
pH 
The patch of every trial formula was dispersed in 10 ml distilled 
water and the pH of the resulting suspension was measured using 
pH meter. (Labtronics LT 11, India). 
Average weight 
Patches (5 no.) of each formula were weighed individually and 
average weight was calculated. 
Drug content 
A patch was dissolved in 10 ml of methanol by sonication for 2 
min. The resulting solution was filtered, diluted suitably with 
PBS and absorbance was recorded spectrophotometrically at 
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246 nm against PBS as blank. The assay was done in triplicate for 
each formulation. 
In vitro permeation studies 
Formulations were subjected to in vitro permeation studies by using 
Franz diffusion cells. PBS was filled up to the brim in the receptor 
chamber of the cell and maintained at 37±0.5 °C with the help of a 
circulating water bath. Donor compartment comprised of the patch. 
Donor and receptor compartments were separated by cellophane 
membrane with 12000 molecular weight cut off. Samples were 
withdrawn at 0.5, 1, 2, 4, 6, 8, and 24 h intervals and replaced with 
the equal quantity of fresh PBS. The drug content in samples was 
analyzed spectrophotometrically at 246 nm after suitable dilution 
with PBS. Fresh medium was replaced in the receptor compartment 
ensuring the absence of any air bubble between the membrane and 
the receptor fluid. Receptor fluid was stirred continuously 
throughout the study with the help of a magnetic stirrer. 
Formulation development with permeation enhancers 
Formulations F1 to F7 were prepared using 5% of various 
permeation enhancer’s viz. Transcutol®, oleic acid, iso-stearic acid, 
benzyl alcohol, dimethyl sulfoxide, propylene carbonate and 
dimethyl isosorbide respectively. The basic composition and method 
of preparation of all these formulations was the same as that of FA1. 
The formulations were subjected to evaluation in a manner 
described under evaluation of TDDS. The values of cumulative doxa 
permeated obtained after in vitro skin permeation studies were fed 
to PCP-Disso-V 3 software to determine the flux of the drug and also 
the release kinetics. 
Accelerated stability study 
Patches were prepared as per formula F1, 
RESULTS AND DISCUSSION  
packed individually in 
aluminum foil sachets and subjected to accelerated stability studies 
for 3 mo at 40±2 °C and 75±5 % RH. The samples were withdrawn at 
1, 2 and 3 mo intervals and subjected to appearance, folding 
endurance, % moisture absorbed, pH, assay and in vitro skin 
permeation studies. Permeation profiles of the stability samples 
were compared by applying two way ANOVA (*p<0.05) using 
GraphPad Prism software version 5.01. 
Skin irritation study 
After obtaining the approval of Institutional Animal Ethics 
Committee (ICP/IAEC/2017-18/03), 5 New Zealand male albino 
rabbits were procured from LACSMI Biofarm Pvt Ltd, Pune, India. 
The animals were allowed to acclamatize for the period of 7 d. TDDS 
of formulation F1 was applied to the left-hand dorsal surface of the 
shaved intact skin of the rabbits. A placebo patch formulation 
prepared with the same formula as F1 but without the drug was 
applied in a similar manner to the right-hand dorsal surface of these 
5 rabbits. The sites were occluded with gauze piece and an adhesive 
tape. The formulations were removed after 4 h of application. Skin 
reaction at the sites of application in the form of erythema or edema 
was assessed and scored as per Draize protocol at 1, 24, 48, 72 h, 7 
and 14 d [15, 25]. The scores of both test and placebo sites were 
compared statistically using Student's two-tailed t-test (*p≤ 0.05).  
Standard plot of doxa 
The plot was found to be linear in the concentration range of 2-10 µg/ml 
at 246 nm. Regression coefficient was found to be 0.9989 indicating the 
linearity of absorbance in the studied concentration range. 
Selection of polymer combinations for development of TDDS 
HPMC K100LV, HPMC K4M, PVP K30, and EC were used in 
combination as film formers and patches were prepared using various 
ratios of these polymers. Methanol was used as a vehicle since selected 
polymers, as well as doxa, showed good solubility in it. Moreover, 
methanol being volatile evaporatd quickly to leave behind the the 
polymeric film. Water, PEG 400 and glycerin were used as plasticizers 
to retain the integrity of the patch as well as to contribute flexibility. 
Patches of compositions A3, B3, C3 very thin and fragile owing to the 
lower concentration of the polymers. Patches prepared using formulae 
B4, B5, D4, D5 showed small lumps upon drying which could be 
attributed to the poorer solubility of EC in the selected vehicle. 
Combinations C1, C5, D1 containing HPMC K4M in higher proportion 
exhibited high viscosity and hence were difficult to pour in the plate. 
Hence these compositions were not taken up for further studies. 
Evaluation of placebo patches 
Patches of compositionsA1, A5, B1, D2 and D3 had acceptable clarity 
and appearance. The thickness of all these patches was in the range 
of 0.27 to 0.33 mm. Folding endurance of the patches was found to 
be in the range of 144 to 170. A higher value of folding endurance 
indicates a better physical strength of the patch and resistance to 
breaking during clinical use. 
Moisture absorption test gives an indication of the physical stability 
of the patch at high relative humidity whereas moisture loss 
indicates the behavior of patch when exposed to excessively dry 
conditions. Both these tests help in the selection of appropriate 
formulation components, packaging material, and storage condition 
for the formulation. Moisture absorbed by various formulations was 
found to be in the range of 11 to 18 % whereas moisture loss was 
found between 1.9 to 6 %. HPMC and PVP K30 based formulations 
showed higher moisture uptake as well as moisture loss as 
compared to that of patches B1 and B2. This could be attributed to 
the presence of EC in these compositions which inherently is less 
sensitive to moisture as compared to HPMC.  
Development of TDDS of doxa 
The compositions A1, A5, B1, D2, D3 
The results of the evaluation parameters of the TDDS are shown in 
table 3. 
formed transparent, clear 
patches of high folding endurance and better physical stability at 
reasonable conditions of RH. Hence these compositions were chosen 
for further formulation development studies. The recommended oral 
extended release dose of doxa is 4 mg once a day [8]. TDDS of doxa 
was hence prepared in a way that each 2.5 cm x 2.5 cm patch 
contained doxa (4.85 mg) equivalent to 4 mg of doxazosin free base. 
Evaluation of TDDS 
 
Table 3: Evaluation of TDDS of doxa 
Evaluation parameter FA1 FA5 FB1 FD2 FD3 
pH 6.3 6.2 6.1 6.4 6.5 
Average weight* (mg) 225±11 223±9 228±14 195±12 155±11 
Assay (%)# 99±1.1 99.1±0.6 100±.6 101±0.1 98±0.5 
*The values are mean±standard deviation of n=5 # The values are mean±standard deviation of n=3 
 
In vitro skin permeation study was carried out for patches of all the 
five formulations by using Franz diffusion cells. Permeation profiles 
are shown in fig. 1. 
TDDS of FA1 showed maximum and that of FD3 showed minimum 
permeation of doxa as compared to the rest. Higher permeation from 
FA1 could be owing to the hydrophilic polymer matrix of lower viscosity 
grade allowing the higher release of drug from the formulation which in 
turn resulted in greater flux across the barrier membrane. Formulation 
FD3 contained HPMC K4M and EC. The higher viscosity of the former 
and the hydrophobicity of the later polymer could have retained the 
drug within the formulation thus affecting its permeation significantly.  
Formulation FA1 was selected for further studies. 
Kulkarni et al. 




Fig. 1: In vitro permeation study of doxa fromTDDS formulations. The values are mean±standard deviation of n=3. FA1-patch made with 
HPMC K100 LV and PVP K 30 in 3:1 ratio, FA5-patch made with HPMC K100 LV and PVP K 30 in 2:2 ratio, FB1–patch made with HPMC 
K100 LV and EC in 3:1 ratio, FD2-patch made with HPMC K4M and EC in 3:1 ratio FD3-patch made with HPMC K4M and EC in 1:1 ratio 
 
Formulation development with permeation enhancers 
Permeation enhancers are used routinely in cosmetic, dermal and 
transdermal formulations in order to increase the rate and extent of 
permeation of active into or across the skin. Enhancers like 
Transcutol®, benzyl alcohol, dimethyl isosorbide enhance the 
partitioning of the drug into the skin [26, 27]. Dimethyl sulfoxide, 
propylene carbonate are polar, aprotic solvents which are known to 
extract lipids and/or keratin from the skin thereby improving the 
permeation. Fatty acids like oleic acid, isostearic acid fluidize the 
lipid bilayer by incorporating themselves into its organized 
structure [28]. TDDS of doxa were prepared using all these 
enhancers in order to evaluate their impact on its permeation.  
In vitro permeation profiles of formulation, FA1 and F1 to F7 are 
depicted in fig. 2. 
 
 
Fig. 2: In vitro permeation of doxa from TDDS containing various permeation enhancers. The values are mean±standard deviation of n=3. 
Key: FA1-TDDS with no enhancer, F1-with Transcutol®, F2-with oleic acid, F3-with isostearic acid, F4-with benzyl alcohol, F5-with 
dimethyl sulfoxide, F6-with propylene carbonate, F7-with dimethyl isosorbide 
 
Transcutol®, benzyl alcohol and dimethyl sulfoxide remarkably 
improved the permeation of doxa as compared to the absence of 
enhancer in the formula FA1. The enhancement in permeation could 
be attributed to higher diffusion of the drug from the polymeric 
matrix in presence of Transcutol® [28, 29]. Interaction of dimethyl 
sulfoxide and even benzyl alcohol with lipophilic membrane could 
be a reason for better permeation of drug across the membrane [30]. 
Incorporation of oleic acid, isostearic acid, dimethyl isosorbide and 
Kulkarni et al. 
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propylene carbonate in formulations F2, F3, F6, and F7 respectively 
showed suppression of permeation of the drug. This could be 
attributed to the enhancement of solubility of the drug in the 
polymeric matrix in presence of either of these enhancers. Increased 
solubility of the drug in the formulation could have led to a 
reduction in thermodynamic activity of the drug, in turn, decreasing 
its partitioning into the membrane [29]. Transcutol® and dimethyl 
sulfoxide enhanced the permeation of doxa to a greater extent. The effect 
of various enhancers expressed in terms of average flux can be 
summarized as Transcutol® (10.6±2.1 µg/cm2h)>dimethyl sulfoxide 
(10.17±1.2 µg/cm2h)>benzyl alcohol (9.55±1.3 µg/cm2h)>no enhancer 
(8.86±1.1 µg/cm2h)>dimethyl isosorbide (8.21±1.5 µg/cm2h) 
>Isostearic acid (7.82±1.4 µg/cm2h)>propylene carbonate (7.67±1.4 
µg/cm2h)>oleic acid (7.12 µg±0.8/cm2
Though the use of artificial lipophilic membrane helped in 
distinguishing the impact of enhancer on the permeation of doxa, it 
would be best to use the human cadaver skin to understand the 
exact influence of the enhancer on the flux of the drug. The actual 
presence of the components like lipids, ceramides, and keratin of 
human skin are difficult to mimic by a cellophane membrane. 
Moreover, though formulation F1 showed the highest value of drug 
permeation, there was no statistically significant difference in the 
flux of doxa from formulations F1, F4 and F5 containing 
Transcutol®,  benzyl alcohol and dimethyl sulfoxide respectively. 
Use of in vivo studies is expected to distinguish the influence of these 
enhancers in a better way.  
h).  
In order to deduce the kinetics of in vitro permeation of drug from 
the eight formulations, various equations were used, such as the 
zero-order rate equation, which describes the systems where the 
release rate is independent of the concentration of the drug. The first 
order equation describes the release from systems where 
dissolution rate is dependent on the concentration of the dissolving 
species. The Higuchi’s square root equation describes the release 
from systems where the drug is dispersed in a polymeric matrix, and 
the rate of drug release is related to the rate of drug diffusion from 
the matrix [31]. 
Permeation profiles of the TDDS showed the closest fit to Higuchi’s 
equation as indicated by the values of correlation coefficient closest 
to unity. This postulated diffusion based permeation of the drug 
from the polymeric matrix formulations. 
Accelerated stability study  
The stability samples of formulatiuon F1 at 1,2 and 3 mo intervals 
showed acceptable appearance and folding endurance in the range 
of 165-170 indicating good physical stability. pH of the samples was 
between 6.2 to 6.4 and drug content in the range of 98 to 100%. In 
vitro permeation profiles of stability samples when compared with 
that of the initial did not show significant difference thus confirming 
the robustness of the formulation at accelerated conditions of 
temperature and humidity. 
Skin irritation study 
Draize skin irritation protocol was used to study the skin irritation 
effect of the TDDS. Application of formulation F1 to the shaved back 
portion of New Zealand albino rabbits did not lead to any erythema 
or edema as compared to the placebo formulation which served as a 
control. The scores of erythema and edema calculated over the 
observation period of 14 d for test and control were zero. This 
confirmed the innocuous nature of the formulation and its safety in 
application to the skin. 
CONCLUSION 
TDDS of doxa formulated with HPMC K100LV and PVP K-30 in the 
ratio of 3:1 and containing either 5%Transcutol®, 5% dimethyl 
sulfoxide or 5% benzyl alcohol showed promising in vitro skin 
permeation profiles over a 24 h time period. TDDS containing 
Transcutol® when subjected to accelerated stability studies showed 
acceptable physical and chemical stability traits with no significant 
changes in permeation profile. In vivo skin irritation test of the 
formulation proved its safe, nonirritating and innocuous nature. 
Pharmacokinetic studies would be essential to establish the 
potential of developed TDDS in delivering the therapeutic 
concentrations of doxa for the treatment of BPH and hypertension. 
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